The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma

被引:3
|
作者
Zhang, Lishuo [1 ]
Di, Longjiang [2 ]
Liu, Jinhui [3 ]
Lei, Xianli [4 ]
Gu, Maoli [1 ]
Zhang, Wenjing [3 ]
Wang, Yufu [3 ]
机构
[1] Harbin Med Univ, Dept Urol, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China
[2] Southern Med Univ, Coll Basic Med, Guangzhou, Guangdong, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Harbin, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; long non-coding RNA; cuproptosis; prognosis; immunotherapy; CLASSIFICATION;
D O I
10.3389/fgene.2023.1039813
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cuproptosis is a new form of cell death, the second form of metal ion-induced cell death defined after ferroptosis. Recently, cuproptosis has been suggested to be associated with tumorigenesis. However, the relationship between cuproptosis and patient prognosis in clear cell renal cell carcinoma (ccRCC) in the context of immunotherapy remains unknown. The aim of this study was to investigate the correlation between cuproptosis-related long non-coding RNA (lncRNA) and ccRCC in terms of immunity as well as prognosis. Clinical information on lncRNAs associated with differences in cuproptosis genes in ccRCC and normal tissues was collected from The Cancer Genome Atlas (TCGA) dataset. Univariate Cox regression was used to screen lncRNAs. A total of 11 lncRNAs closely associated with cuproptosis were further screened and established using the least absolute shrinkage and selection operator (LASSO) algorithm and multivariate Cox regression, and the samples were randomly divided into training and test groups. A risk prognostic model was constructed using the training group, and the model was validated using the test group. We investigated the predictive ability of the prognostic risk model in terms of clinical prognosis, tumor mutation, immune escape, immunotherapy, tumor microenvironment, immune infiltration levels, and tumor drug treatment of ccRCC. Using the median risk score, patients were divided into low and high-risk groups. Kaplan-Meier curves showed that the overall survival (OS) of patients in the high-risk group was significantly worse than low-risk group (p < 0.001). Receiver operating characteristic (ROC) curves further validated the reliability of our model. The model consistently and accurately predicted prognosis at 1, 3, and 5 years, with an AUC above 0.7. Tumor cell genes generally precede morphological abnormalities; therefore, the model we constructed can effectively compensate for the traditional method of evaluating the prognosis of patients with renal cancer, and our model was also clinically meaningful in predicting ccRCC staging. In addition, lower model risk scores determined by mutational load indicated a good chance of survival. The high-risk group had greater recruitment of immune cells, while the anti-immune checkpoint immunotherapy was less efficacious overall than that of the low-risk group. Tumor and immune-related pathways were enriched, and anti-tumor agents were selected to improve the survival of ccRCC. This prognostic risk model is based on the levels of cuproptosis-associated lncRNAs and provides a new perspective in the clinical assessment and precise treatment of ccRCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma
    Chen, Zhuo
    Liu, Xiao
    Zhu, Zhengjie
    Chen, Jinchao
    Wang, Chen
    Chen, Xi
    Zhu, Shaoxing
    Zhang, Aiqin
    FRONTIERS IN GENETICS, 2022, 13
  • [42] Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma
    Wu, Zhengqi
    Jin, Mingyue
    Xin, Peng
    Zhang, Hao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma
    Lin, Hang
    Qu, Lingzhi
    Chen, Guanqiu
    Zhang, Chunfang
    Lu, Liqing
    Chen, Yongheng
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [44] Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction
    Rongfen Tai
    Jinjun Leng
    Wei Li
    Yuerong Wu
    Junfeng Yang
    BMC Urology, 23
  • [45] Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction
    Tai, Rongfen
    Leng, Jinjun
    Li, Wei
    Wu, Yuerong
    Yang, Junfeng
    BMC UROLOGY, 2023, 23 (01)
  • [46] Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma
    Su, Yang
    Zhang, Tianxiang
    Tang, Jieqiong
    Zhang, Li
    Fan, Song
    Zhou, Jun
    Liang, Chaozhao
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] A computational prognostic model of lncRNA signature for clear cell renal cell carcinoma with genome instability
    Cui, Tingting
    Guo, Jiantao
    Sun, Zhixia
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2022, 22 (02) : 213 - 222
  • [48] A novel inflammation-associated prognostic signature for clear cell renal cell carcinoma
    Liu, Gangcheng
    Xiong, Donglan
    Che, Zhifei
    Chen, Hualei
    Jin, Wenyi
    ONCOLOGY LETTERS, 2022, 24 (03)
  • [49] Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma
    Pang, Yipeng
    Wang, Yushi
    Zhou, Xinyu
    Ni, Zhu
    Chen, Wenjing
    Liu, Yi
    Du, Wenlong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [50] PRSS53 is a potential novel biomarker related to prognosis and immunity in clear cell renal cell carcinoma
    Zhang, Jiajun
    Liu, Guocheng
    Wang, Wei
    DISCOVER ONCOLOGY, 2025, 16 (01)